Selective kappa antagonist properties of nor-binaltorphimine in the rat mes seizure model

https://doi.org/10.1016/0024-3205(89)90470-0Get rights and content

Abstract

The opioid antagonist properties of nor-binaltorphimine (nor-BNI; 17,17′-Bis (cyclopropylethyl)-6,6′,7,7′-tetradehydro-4,5:4′,5′- diepoxy-6,6′-(imino)[7,7′-bimorphinan]-3,3′,14,14′-tetrol) were evaluated in vivo in the rat maximal electroshock (MES) seizure model. Following s.c. or i.c.v. pretreatment, nor-BNI selectively antagonized the anticonvulsant effects of the kappa opioid U50,488, significantly increasing its ED50 by 2.3 and 4.5 fold, respectively. In contrast, pretreatment with nor-BNI (s.c. or i.c.v.) failed to antagonize the anticonvulsant effects of the selective mu opioid, DAMGO. At the doses and injection routes used, nor-BNI itself had no apparent effect on overt behavior or MES-induced convulsions. These data support the earlier suggestion that the anticonvulsant effects of U50,488 are mediated by kappa opioid receptors and confirm 1) the selectivity of nor-BNI as a kappa antagonist and 2) its applicability as a pharmacological tool in the differentiation of multiple opioid receptors.

References (17)

  • A. Goldstein et al.

    Trends Pharmacol. Sci.

    (1984)
  • R. Cotton et al.

    Eur. J. Pharmacol.

    (1984)
  • P.S. Portoghese et al.

    Life Sci.

    (1987)
  • H.I. Mosberg et al.

    Life Sci.

    (1983)
  • J.S. Shaw et al.

    Life Sci.

    (1982)
  • F.C. Tortella

    Trends Pharmacol. Sci.

    (1988)
  • F.C. Tortella et al.

    Peptides

    (1988)
  • A.E. Takemori et al.

    Ann. Rev. Pharmacol. Toxicol.

    (1985)
There are more references available in the full text version of this article.

Cited by (55)

  • Norbinaltorphimine

    2007, xPharm: The Comprehensive Pharmacology Reference
  • On the mechanism of anticonvulsant effect of tramadol in mice

    2005, Pharmacology Biochemistry and Behavior
View all citing articles on Scopus
View full text